预约演示

更新于：2025-09-24

Metoprolol Tartrate

酒石酸美托洛尔

更新于：2025-09-24

概要

基本信息

简介Metoprolol Tartrate 是一种阻断 β-肾上腺素能受体的药物，它于 1978 年被 AstraZeneca PLC 批准。它主要用于治疗心力衰竭、甲状腺机能亢进、神经循环衰弱和心动过速。这种药物属于称为 β-肾上腺素能受体拮抗剂或 β-受体阻滞剂的药物类别。通过阻断肾上腺素和去甲肾上腺素对心脏和血管的影响，酒石酸美托洛尔减慢心率，降低收缩力，降低血压，最终改善心脏血流量。虽然一般耐受性良好，但一些患者可能会出现头晕、疲劳和呼吸急促等副作用。

药物类型

小分子化药

别名

Metoprolol、Metoprolol tartrate (JP17/USP)、美托洛尔

+ [19]

靶点

β1-adrenergic receptor

作用方式

拮抗剂

作用机制

β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [1]

在研适应症

心律失常肥大型心肌病主动脉夹层+ [8]

非在研适应症

乳腺癌功能障碍

原研机构

AstraZeneca PLC

在研机构

Validus Pharmaceuticals LLC

AstraZeneca PLC

Rubicon Research Ltd.

+ [3]

非在研机构-

权益机构

Recordati SpA

AstraZeneca PLC

最高研发阶段批准上市

首次获批日期

美国 (1978-08-07),

心绞痛高血压心肌梗塞

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C34H56N2O12

InChIKeyYGULWPYYGQCFMP-CEAXSRTFSA-N

CAS号56392-17-7

关联

196

项与酒石酸美托洛尔相关的临床试验

NCT07103655

/ Not yet recruiting临床4期IIT

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.

This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.

开始日期2026-01-01

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

NCT06864234

/ Recruiting临床4期IIT

Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA: a Randomised, Placebo-controlled, Mechanistic Study

The goal of this clinical trial is to learn whether beta-blockers can improve coronary blood flow and reduce resistance in patients with angina and no obstructive coronary arteries (ANOCA).
The main questions it aims to answer are:
* Do beta-blockers improve coronary blood flow in patients with ANOCA?
* Do beta-blockers reduce coronary microvascular resistance in these patients?
Researchers will compare a beta-blocker to a placebo to see if the medication has measurable effects on coronary circulation.
Participants will:
* Receive a beta-blocker or a placebo
* Undergo specialized heart tests (such as coronary flow and resistance measurements) before and after treatment.

开始日期2025-07-03

申办/合作机构-

ITMCTR2025001082

/ Suspended临床4期IIT

A randomized open-label blank controlled multicenter clinical trial of Ginseng GUI PI Pills combined with dexzopicron and metoprolol in the treatment of insomnia with ventricular premature beats (syndrome of deficiency of both heart and spleen)

开始日期2025-06-01

申办/合作机构

哈尔滨医科大学

100 项与酒石酸美托洛尔相关的临床结果

登录后查看更多信息

100 项与酒石酸美托洛尔相关的转化医学

登录后查看更多信息

100 项与酒石酸美托洛尔相关的专利（医药）

登录后查看更多信息

1,156

项与酒石酸美托洛尔相关的文献（医药）

2025-10-01·INTERNATIONAL JOURNAL OF PHARMACEUTICS

The impact of glidant addition on continuous blending of active pharmaceutical ingredients

Article

作者: Vervaet, Chris ; De Man, Alexander ; Vanhoorne, Valérie ; Kumar, Ashish ; Otava, Martin ; De Beer, Thomas ; Van Snick, Bernd ; Verbeek, Tom

Continuous manufacturing (CM) of solid dosage forms in the pharmaceutical industry offers several advantages over batch processing. The most straightforward CM pathway within the pharmaceutical industry is continuous direct compression (CDC), which consists of three main consecutive steps: loss-in-weight feeding, continuous blending and tableting (die-filling and compaction). However, as the majority of the newly developed APIs are cohesive materials with a mean particle size of < 100 μm, a wide particle size distribution (PSD) and a high tendency to agglomerate, they are difficult to handle on CM lines. In this research paper, the impact of a diverse selection of glidants on the continuous blending unit was assessed. Two cohesive APIs (acetaminophen micronized and metoprolol tartrate) and three different glidants (Aerosil^{\protect \relax \special {t4ht=®}} 200, Aerosil^{\protect \relax \special {t4ht=®}} R972 and Syloid^{\protect \relax \special {t4ht=®}} 244 FP) were included. Via multivariate data analysis, quantitative relationships were established between glidant concentration, blending responses (hold-up mass (HM), bulk residence time (BRT), blender fill fraction (BFF %) and relative standard deviation of the blend uniformity (RSD_BU)), blend properties and process settings. The dry-coating of APIs with small quantities of glidants efficiently improved the flowability of cohesive powders, thereby optimizing the gravimetric feeding performance. Dry powder coating of the API altered its bulk properties which affected the bulk properties of the final blend as well as the blending responses (HM, BRT, BFF %). This was mainly attributed to the changes in basic flow energy (BFE), conditioned bulk density (CBD), flowability rate index (FRI) and flow function coefficient (ffc), which are all correlated to HM, BRT and BFF %. It was also observed that glidants did not improve RSD_BU during continuous blending within the investigated experimental space. Moreover, adding higher concentrations of glidants can even increase RSD_BU due to fluidization segregation and less paddle interactions. However, the overal RSD_BU values obtained with the continuous blender were relatively low.

2025-07-01·BIOMEDICAL CHROMATOGRAPHY

Simultaneous Determination of Glibenclamide, Metoprolol Tartrate, and Phenol Red Using HPLC‐PDA: Application in Rat Intestinal Permeability Studies and Its Greenness Assessment Using NEMI, Analytical Eco‐Scale, GAPI, MoGAPI, AGREE, AGREEprep, RAPI, BAGI, and CACI

Article

作者: Sezgin, Burcu ; Aygeyik, Emrah ; Çelebier, Mustafa ; Arli, Göksel ; Musayeva, Fargana ; Kaynak, Mustafa Sinan ; Soyseven, Murat ; Kaval, Berna

ABSTRACT:

This study presents the development and validation of an environmentally friendly HPLC‐PDA method for the simultaneous determination of glibenclamide (GLB), metoprolol tartrate (MET), and phenol red (PR). The method was optimized to ensure high trueness, precision, and robustness, adhering to ICH guidelines. The pKa of GLB was determined using reverse‐phase HPLC under varying pH conditions, providing valuable insights into its physicochemical properties and enhancing its pharmaceutical formulation potential. Intestinal permeability studies of GLB, conducted via the in situ Single Pass Intestinal Perfusion (SPIP) technique, validated the method's applicability in biological systems. In addition to analytical performance, the environmental sustainability of the method was assessed using green metrics, including the Analytical Eco‐Scale, GAPI, MoGAPI, AGREE, AGREEprep RAPI, BAGI, and CACI. The method achieved high scores, reflecting its alignment with the principles of green analytical chemistry and its minimal ecological impact. This dual focus on analytical rigor and environmental responsibility emphasizes the method's potential for broader applications in pharmaceutical and biomedical research. The findings of this study contribute to the ongoing efforts in developing sustainable analytical methodologies. Future research could explore its applicability to other pharmaceutical compounds and expand its use in complex matrices, further promoting environmentally conscious practices in analytical chemistry.

2025-07-01·ANALYTICA CHIMICA ACTA

Multi-interaction (substituted-phenylcarbamate)-hydroxypropyl-β-cyclodextrin chiral stationary phases for liquid chromatography

Article

作者: Zhu, Junchao ; Xu, Wentao ; Xu, Linna ; Cheng, Dongping ; Tong, Shengqiang ; Chen, Songlin ; Ni, Huizhen ; Chu, Chu

BACKGROUND:

(Substituted-phenylcarbamate)-β-cyclodextrin (β-CD) chiral stationary phases (CSPs) showed high enantioselectivity and complementary capabilities compared to polysaccharide-based CSPs in liquid chromatography. Most of the previous works were about preparation and application of (substituted-phenylcarbamate)-β-CD, while very limited works was available reporting modified hydroxypropyl-β-CD (HP-β-CD) used for CSP. As matter of fact, HP-β-CD was more frequently used than native β-CD as chiral selector in many chiral separation techniques. Therefore, it was great of significance to investigate preparation of multi-interaction (substituted-phenylcarbamate)-HP-β-CD CSPs and its application in chiral separation.

RESULTS:

Three new multi-interaction (substituted-phenylcarbamate)-HP-β-CD CSPs were prepared and investigated, including (3-chloro-4-methylphenylcarbamate)-HP-β-CD CSP, (4-chloro-3-methylphenylcarbamate)-HP-β-CD CSP and (5-chloro-2-methylphenylcarbamate)-HP-β-CD CSP. The structure and morphology of the three chiral selectors as well as their stationary phase were characterized by ¹H NMR spectra, elemental analysis, infrared spectroscopy, scanning electron microscopy and thermogravimetric analysis. Degree of substitution, stability, repeatability and reproducibility of the (substituted-phenylcarbamate)-HP-β-CD CSPs were investigated. A total of 56 racemic compounds were examined on the three (substituted-phenylcarbamate)-HP-β-CD CSPs using reversed-phase elution mode. It was found that enantioselective recognition capability of the three (substituted-phenylcarbamate)-HP-β-CD CSPs was greatly improved compared with that of traditional HP-β-CD CSPs, which was demonstrated by the number of successful enantioseparated racemates and increased enantioseparation efficiency. Applications of the three CSPs in high performance liquid chromatographic enantioseparations indicated that each of them showed different enantiorecognition ability toward different type of racemic structures, which showed high complementary enantiorecognition ability with traditional β-CD-based CSPs.

SIGNIFICANCE:

An efficient one-pot reaction strategy for synthesis of (substituted-phenylcarbamate)-HP-β-CD CSPs was developed. It was found that enantiorecognition and peak resolutions (Rs) were greatly improved compared with traditional HP-β-CD CSP and β-CD CSP. The improved chiral separation performance of multi-interaction HP-β-CD CSPs was demonstrated, providing valuable insights for the development of efficient chiral separation methods while expanding the potential applications of HP-β-CD in chiral liquid chromatography.

276

项与酒石酸美托洛尔相关的新闻（医药）

2025-09-19

·国际糖尿病idiabetes

急性心梗刮起“电风暴”！6旬老人胸闷17余年，午睡突发意识丧失伴抽搐，差点一觉“睡”过去了

点击“蓝字”关注我们急性非ST段抬高型心肌梗死属急性冠状动脉综合征（ACS）的一种类型，往往在心电图检查时表现为急性心肌缺血性损伤，但不伴ST段抬高。有研究表明，心肌梗死后并发心室颤动（室颤）的发生率为4.2%，并发室颤的近期病死率（40.9%）远高于无并发室颤者（2.5%）[1]。临床上，心室电风暴（VES）严重威胁着患者的生命，常常导致患者猝死，医师人员必须严密观察患者病情变化，迅速、准确识别。本文报道一例以心室电风暴为首发表现的急性非ST段抬高型心肌梗死病例，以供临床参考。一、病历摘要患者，男性，65岁，主因“阵发胸闷17年，发作性意识丧失2天”于2022年2月26日急诊入院。患者2005年2月劳累后出现胸闷，持续休息6~7分钟后可缓解，于我院诊断为不稳定型心绞痛，行冠脉造影检查示：双支血管病变（累及LAD、LCX），LAD近段70%~80%节段狭窄，置入支架一枚，LCX中远段60%节段性狭窄，未干预，术后胸闷症状好转。术后4个月发作“急性前间壁心梗”，行急诊冠脉造影检查示：LAD原支架100%闭塞，给予球囊扩张治疗后血流恢复至TIMI-3级，术后规律冠心病二级预防治疗。 2016年因再发胸闷入院，复查冠脉造影提示：三支血管病变（累及LAD、LCX、RCA），LADp原支架近段40%~50%再狭窄，LCXp、D1d 70%~90%狭窄，于LCX、D1各置入支架一枚，术后继续二级预防用药，未再发作明显胸闷等不适。此次于2天前午睡时突发意识丧失、呼之不应，伴大汗及上肢抽搐，无大小便失禁，持续约10分钟后自行缓解，未就医。1天前午睡时上述症状再发，持续2~3分钟后好转，伴胸痛、心悸及乏力，来我院急诊，心电图提示：窦性心律，心率71次/分，未见ST-T改变，化验TnI 0.036 ng/ml，略增高；患者于急诊留观期间心电监护发现室速5次，室速时感胸痛及心悸，给予利多卡因、胺碘酮静脉注射均无法控制，200J同步电复律可转复，为进一步诊治收入我科。既往史：高血压病史20余年，血压最高190/140 mmHg，不规律服药，未监测血压；2型糖尿病病史5年余，现服用阿卡波糖治疗，血糖控制不佳；血脂代谢异常病史20余年，间断服用辛伐他汀降脂；半年前因服用阿司匹林出现鼻出血而自行停用。吸烟50余年，平均每天15~20支，未戒烟；否认饮酒史。父母生前均有有高血压、糖尿病病史。体格检查：体温36℃，脉搏70次/分，呼吸16次/分，血压：左上肢155/72 mmHg，右上肢145/65 mmHg，BMI 22kg/m2，腹围86 cm。神清，精神弱，听诊双肺呼吸音粗，未闻及干湿啰音，无胸膜摩擦音。心前区无异常隆起及凹陷，心尖搏动位于胸骨左侧第五肋间锁骨中线内0.5 cm，各瓣膜区未触及震颤，叩诊心界不大，听诊心率70次/分，律齐，P2=A2，第一心音正常，各瓣膜听诊区未闻及病理性杂音及额外心音，无心包摩擦音。全腹软，无压痛、反跳痛，肝脾肋下未触及，肠鸣音4次/分。双下肢不肿。辅助检查： 1.实验室检查：谷丙转氨酶38 U/L，谷草转氨酶32 U/L，白蛋白35.5 g/L，肌酐78.7 μmol/L，尿素氮2.79 mmol/L，钾3.74 mmol/L，镁1.07 mmol/L，低密度脂蛋白胆固醇1.95 mmol/L，糖化血红蛋白7.7%，D-二聚体0.7 mg/L，肌酸激酶12 U/L，肌酸激酶同工酶2.3 ng/ml，肌钙蛋白I 0.638 ng/ml，肌钙蛋白T 0.926 ng/ml，NT-proBNP 2142 pg/ml；血气分析：PO2 78.1 mmHg，PCO2 41.8 mmHg，pH 7.394。 2.心电图（未发作时）：窦性心律，未见明显ST-T改变，QT间期=440 ms，QTc=463。 3.监护心电图（发作时）：室性心动过速。 4.超声心动图：左心房前后径3.5 cm，左室舒张末期内径5.5 cm，左室射血分数50%，左室前壁、前室间隔运动减弱。 5.胸部增强CT：双肺炎症不除外，肺气肿，双侧少量胸腔积液。 6.头颅平扫CT：未见明显异常。诊断：①冠状动脉粥样硬化性心脏病。②急性非ST段抬高型心肌梗死。③陈旧性前间壁心肌梗死。④心律失常、持续性室性心动过速。⑤三支血管病变（累及LAD、LCX、RCA）、LAD及LCX-PCI术后。⑥高血压3级（很高危）。⑦2型糖尿病。⑧血脂代谢异常。二、诊疗方案与经过患者收入CCU严密监护，给予静脉输注氯化钾及硫酸镁维持电解质稳定。持续静脉泵入胺碘酮、艾司洛尔的情况下仍发作持续性室性心动过速达3次，均通过电复律恢复窦性心律。随后给予患者持续静脉泵入尼非卡兰维持窦性心律。虽然患者此次发病无明显胸闷、胸痛等心肌缺血表现，心电图未见ST-T动态变化，但结合患者既往冠心病病史，仍首先考虑其反复发作室性心动过速与心肌缺血相关可能性最大，遂于入院第二天行冠状动脉造影检查。造影示LADo 80%~90%局限性狭窄，LADp于高位对角支发出后次全闭塞，前向血流TIMI 1级（图1）。图1. 造影结果高位D1o 50%~60%局限性狭窄，D1d原支架通畅，LCXd原支架通畅，前向血流TIMI 3级；RCA可见多处轻中度狭窄，前向血流TIMI 3级，并可见RCA向LAD发出2级侧支显影。术中成功开通LAD病变并植入支架两枚（图2）。图2. 植入支架后造影术后给予阿司匹林、氯吡格雷双联抗血小板等冠心病二级预防治疗。术后患者未再发作室性心动过速，生命体征平稳，于术后第四天出院。出院后患者恢复良好，未再出现意识丧失，一般活动均可耐受，定期门诊复查。三、病例分析 2006年《美国心脏病学学会（ACC）/美国心脏协会（AHA）/欧洲心脏病学学会（ESC）室性心律失常的处理与心脏性猝死的预防指南》中首次明确了心室电风暴（VES）的定义[2]：VES是指24 h内发生2次或2次以上的室性心动过速或心室颤动，同时伴血路动力学不稳定，需要电复律和电除颤紧急治疗的临床症候群，其中以器质性心脏病为其主要病因。近年来，随着埋藏式心律转复除颤器（implantable cardioverter defibrillator，ICD）的广泛应用，2017年《室性心律失常中国专家共识》心室电风暴的定义已经做了更新[3]：24小时内发作3次或3次以上明确的室性心动过速或心室颤动，需要抗心动过速起搏或电击治疗的临床症候群。该病起病急骤、死亡率高、预后差，是心源性猝死的重要机制之一。心室电风暴常发生于以下几种情况：①器质性心脏病如急性冠脉综合征、心肌炎、心肌病，其中急性冠脉综合征最为常见。②非器质性心脏病如长QT综合征、Brugada综合征、特发性室性心动过速，与离子通道病变有关。③非心源性疾病如急性出血性脑卒中、急性呼吸衰竭、急性肾衰竭、急性胰腺炎，通过低氧血症、急性应激状态引起自主神经功能紊乱、电解质失衡等诱发心室电风暴。④精神心理性疾病。⑤ICD植入术后。在心室电风暴发作期，尽快进行电除颤和电复律是恢复血流动力学稳定的首要措施，尤其对于室颤、多形性室速等患者更为重要。但是，过度频繁地实施电除颤易导致心肌损伤、心肌细胞凋亡，出现进行性心功能衰竭，加重心律失常的发作。因此，在治疗心室电风暴的过程中，不能完全依赖电复律，必须将电复律与药物治疗结合起来。在心律转复后，必须进行合理的心肺脑复苏治疗，以保证重要脏器的血供。及时静脉应用有效的抗心律失常药物，可以控制心室电风暴的发作和减少心室电风暴的复发。首选药物为β受体阻滞剂（常选用美托洛尔），《室性心律失常的诊疗和SCD预防指南》（ACC/AHA/ESC）指出，静脉注射β受体阻滞剂为治疗心室电风暴的唯一有效方法[2]。次选为胺碘酮，必要时β受体阻滞剂和胺碘酮二者可联合应用。该患者在静脉泵入胺碘酮、艾司洛尔的情况下仍反复发作室速，遂应用了亚类抗心律失常药物、钾离子通道阻滞剂盐酸尼非卡兰，该药相较于胺碘酮，对心肌细胞除极和传导速度几乎没有影响，不存在负性变力作用，一般不会引起低血压和心动过缓，起效快、复律时间更短、成功率更高，因此更适合器质性心脏病同时伴有血流动力学不稳定的患者。该患者在应用尼非卡兰后未再发生室速，为其尽快行冠脉介入治疗提供了先决条件。相较于急性ST段抬高型心肌梗死，非ST段抬高型心肌梗死出现室速、室颤等相对不多见。此患者在既往陈旧前间壁心肌梗死基础上，此次发作心室电风暴；尽管发病前无心肌缺血症状且心电图未见新发缺血改变，但仍应该首先考虑为心肌缺血继发室性心动过速。针对病因和诱因治疗是处理心室电风暴的根本所在，尤其对于缺血性电风暴需尽快进行血运重建，同时改善心功能、维持内环境稳定等。该患者于发病48小时内行冠状动脉造影检查，发现LAD次全闭塞，成功开通后未再发作室速。该患者本身为“三高”患者，多次反复住院，追究其原因主要是药物治疗的依从性差，血压、血糖、血脂三项指标均未得到很好的监控和随访，对待这种患者，应加强出院时的宣教，阐明利害，冠心病的根本治疗不是靠支架与手术，务必从改善生活方式与控制危险因素入手，加强冠心病二级预防的用药与随访。参考文献（上下滑动可查看） [1] Aizawa Y, Chinushi M, Hasegawa K, et al. Electrical storm in idiopathic ventricular fibrillation is associated with early repolarization.J Am Coll Cardiol. 2013;62(11):1015-1019. [2] ZIPES DP, CAMM AJ, BORGGREFE M, et al. ACC/AHA/REC 2006Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac death; a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Managementof Patients With Ventricular Arrhythmias and the Preventions of Sudden Cardiac Death) : developed in collaboration with the European Heart Rhythm Associationand the Heart Rhythm Society. Circulation, 2006, 114 (10) : 385-484. [3] 曹克将,陈明龙,江洪,等.室性心律失常中国专家共识[J].中国心脏起搏与心电生理杂志,2016,30(04):283-325. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际循环》编辑部）

临床研究临床终止

2025-09-15

·鼎科医疗

「刻痕∞可能」刻痕球囊在LAD钙化病变介入治疗中应用一例

本病例术者：佟铁壁沈阳市第十人民医院心脏内科随着《血管介入特殊球囊行业现状与发展趋势蓝皮书》的发布，特殊球囊作为新一代球囊扩张导管，已成为血管介入治疗的重要解决方案。为探讨应对冠脉血管各种复杂病变时，定向刻痕球囊如何与其他器械相配合给患者带来更优的预后，鼎科医疗特推出「刻痕∞可能」病例周，从临床角度剖析定向刻痕球囊在冠脉介入治疗的实际作用，以期为未来诊疗提供新思路和新方法，造福更多临床患者。患者信息（女 71岁）主诉：反复胸痛2个月，加重3天现病史：近2个月来自觉发作性胸闷，心前区疼痛，抚顺市中心医院心电图提示：窦性心律，ST-T改变。冠状动脉CTA：LAD钙化斑块，重度狭窄，RCA中度狭窄，药物治疗无好转，轻微活动后胸闷，心前区疼痛发作，严重时含服救心丸可缓解。既往史：高血压病史20年，最高：180/90mmHg，平素口服氨氯地平治疗，血压控制于140-150/80-90mmHg，否认糖尿病史。查体：血压：130/70mmHg，双肺未及啰音，心界不大，心率：80次/分，未及杂音，双下肢无浮肿。入院诊断：术前诊断：冠心病，不稳定性心绞痛，高血压3级（很高危组）术前分析患者临床不表现未为劳累型心绞痛，外院冠状动脉CTA提示多支病变。手术目标：主要目标：明确冠状动脉狭窄。次要目标：针对狭窄进一步介入治疗。手术策略/方案： 1. 冠脉造影明确病变； 2. 针对罪犯血管导丝通过后，进行IUVS评估，拟进一步启动特殊球囊或旋磨预处理后植入支架或药物球囊处理。辅助检查影像描述：心电图：窦性心律，Ⅱ Ⅲ AVF异常Q波。影像描述：外院心脏彩超：LVD：45mm，LVEF：56%. 室间隔及左室心尖变并薄。诊断： 1，冠心病不稳定型心绞痛 2，高血压3级（很高危组）手术过程 LAD近段钙化斑块，99%全闭塞狭窄，血流TIMI0-1级 Runthrough导丝通过困难，进入假腔 XT-R导丝不能通过钙化狭窄换用XTA导丝通过微导管推送造影证实真腔 1.0*10mm球囊10-12atm逐级扩张 2.0*15mm球囊扩张复查造影见近段夹层，仍钙化斑块，70-80%狭窄窄，血流TIMI3级 LAD术前：IVUS：近中段偏心钙化斑块，MLA：2.25mm²，斑块负荷：79%，90%狭窄，血流TIMI3级鼎科DK Score™ 2.5*15mm冠脉刻痕球囊10-14atm扩张3次鼎科DK Score™ 2.5*15mm冠脉刻痕球囊10-18atm扩张3次 LAD近中端3.0*33mm支架定位 LAD近中段3.0*12mm后扩球囊18-22atm扩张 LAD近中段支架扩张满意，无夹层，血流TIMI3级术后LAD复查IUVS：支架贴壁可，支架内管腔面积：9.10-9.54mm² 术后随访出院口服药物情况：阿司匹林 100mg qd 替格瑞洛 90mg bidpo 瑞舒伐他汀 10mg qdpo 依洛尤单抗注射液 140mgq2wIH 雷贝拉唑钠肠溶胶囊 10mg qdpo 美托洛尔缓释片 23.75mg qdpo 病例总结病例特点 LAD近段钙化斑块，普通球囊扩张后夹层出现。术前评估要点：进行影像学评估，发现偏心钙化斑块，充分预处理后，救治及时，未出现严重并发症。手术策略/技术要点：当钙化程度为轻度时，可直接刻痕球囊预处理，利用其三角镍钛刻痕件对斑块进行定向扩张打开病变。当钙化程度为中重度时，可利用旋磨联合刻痕球囊，先用旋磨预处理打磨钙化表面后换用刻痕球囊定向扩开钙化环达到，1+1＞2的效果，为后续支架或药物球囊的使用打好基础。器械特点/使用技巧刻痕球囊对于出现钙化夹层后通过性能优于切割球囊。专家简介佟铁壁沈阳市第十人民医院主任医师、医学硕士沈阳市第十人民医院心脏中心主任胸痛中心、心衰中心、房颤中心医疗总监从事心脏介入手术工作20余年，年独立介入手术1000余例。对冠心病、急性心肌梗死的介入治疗；严重心律失常的心脏起搏治疗；顽固性心力衰竭、高血压的药物治疗具有丰富的临床工作经验。现任：中国微循环医学学会转化医学专业委员会委员中国老年医学数字诊疗分会委员中国研究型医院学会孕产期母儿心脏病专业委员会常务委员辽宁省细胞生物学会康复分会常务理事；辽宁省医学会心血管分会第九届届委员会冠心病学组委员辽宁省预防医学会第一届动脉硬化疾病预防与控制专业委员会委员辽宁省基层卫生协会胸痛中心建设专业委员会（第二届）委员辽宁省细胞生物学会老年心脏病分会委员辽宁省心源性卒中防治建设联盟委员辽吉黑房颤冷冻消融俱乐部常务理事沈阳医学会医疗损害鉴定专家库成员曾获“辽宁省自然科学基金”1项在国家级期刊发表论文18篇（其中核心期刊6篇,SIC1篇）获国家实用新型专利5项参编医学专著2部科室简介沈阳市第十人民医院心脏中心是集胸痛中心、心衰中心、房颤中心、心血管重症单元于一体的创新团队，以提高心血管疾病临床诊治及科学研究水平为首要任务，成功构建心脏诊疗“三位一体”多中心医学诊疗模式。以胸痛中心为基础的急救绿色通道，以房颤中心为导向的心律失常诊疗平台；以心衰中心为模版的慢性病管理体系，打造多个学科技术交流、融合的平台。构建以胸痛中心为基础的心血管病绿色通道，构架院前急救、院内急诊、重症监护“三环结构”，为患者赢得最佳治疗特别是专科治疗时间，降低死亡率；同时开展“一站式”冠心病介入手术，患者不用再多次转运，从而降低治疗风险已经开展：冠状动脉介入治疗(急诊PCI、平诊PCI、IUVS、FFR、冠状动脉旋磨术等)，心脏电生理治疗（心房颤动冷冻消融，室上性、室性心动过射频速消融等），心脏起搏治疗（临时心脏起搏、单、双腔永久起搏、ICD、CRT-D等）。顽固性心力衰竭合并肾功能损伤连续超滤治疗（CRRT）、心衰超滤治疗；抢救了众多危急重症患者。以提高心血管疾病临床诊治及科学研究水平为首要任务，关注心血管疾病的防治、新技术的应用推广和转化型研究。学科带头人：佟铁壁，医学硕士，主任医师。原北部战区总医院和平院心内科主任。年独立介入手术1000余例。对冠心病、急性心肌梗死的介入治疗、严重心律失常的心脏起搏治疗、顽固性心力衰竭、高血压的药物治疗具有丰富的临床工作经验。王艳丽，主任医师，医学硕士。临床工作近30年，主要专业方向心脏康复、心力衰竭重症治疗。施文贺，主任医师，专注于心血管疾病临床医疗、教学及科研工作，有丰富的心律失常、心力衰竭疾病诊治经验，擅长心血管急危重症抢救治疗，熟悉各种心律失常的微创手术及药物治疗。心脏中心现有医护人员30名，其中医生10名，科室有高级职称医师8名，是一支由博士后、博士、硕士等高素质高学历医生组成的医疗团队。护士20名，在杨天舒护士长带领的护理团队以精湛的护理技术，耐心细致的工作热情，为广大患者提供最优质的护理服务。

2025-09-05

·Firstwordpharma

In third cardiometabolic deal, Hengrui teams up with US-based newco

Jiangsu Hengrui Pharmaceuticals' cardiometabolic portfolio continues to be a popular place for US pharmas and biotechs alike to go shopping for assets. The Chinese drugmaker on Friday announced a new licensing deal worth about $1.1 billion in biobucks with Braveheart Bio, a stealthy startup funded by Forbion and OrbiMed.Braveheart will receive exclusive, ex-China rights to HRS-1893, a small molecule cardiac myosin inhibitor that's already begun Phase III testing for obstructive hypertrophic cardiomyopathy (oHCM). The newco will hand over $65 million upfront, comprising a $32.5-million cash payment and $32.5 million in Braveheart shares, plus $10 million after the tech transfer completes. Hengrui stands to receive up to $1 billion in development and commercial milestones, and is also eligible for royalties on net sales. It retains rights to HRS-1893 in China, Hong Kong, Macao, and the Taiwan region.Gunning for best-in-classAccording to Braveheart CEO Travis Murdoch, data presented at the European Society of Cardiology (ESC) meeting this week bolstered the company's conviction in HRS-1893.Results from a Phase I study showed that the cardiac myosin inhibitor "rapidly and effectively" reduced resting and Valsalva left ventricular (LV) outflow tract gradient, while keeping LV ejection fraction within a safe range. "We believe that [HRS-1893] may confer best-in-class properties among cardiac myosin inhibitors," said Murdoch — though the compound may have stiff competition for the best-in-class crown. Cytokinetics is already racing to dethrone Bristol Myers Squibb and its first-to-market cardiac myosin inhibitor, Camzyos (mavacamten). In its own ESC presentation, Cytokinetics said its entrant in the space, aficamten, significantly improved peak oxygen uptake versus metoprolol, the oHCM standard of care. Deal spree The agreement with Braveheart marks Hengrui's third recent licensing deal for a cardiometabolic asset (see – Spotlight On: China gains traction as hub for cardiometabolic deals).Last year, the firm signed away ex-China rights for GLP-1/GIP receptor agonist HRS9531 to Kailera Therapeutics, another secretive US newco. The partners presented Phase III data in July showing that the once-weekly injection led to placebo-adjusted weight loss of 16.3% after 48 weeks. Hengrui also has a tie-up with Merck & Co. for small molecule Lp(a) inhibitor HRS-5346. The pharma paid $200 million upfront in March for the candidate, which is being evaluated in a Phase II cardiovascular disease study in China. Hengrui is also eligible for up to $1.77 billion in milestones, as well as sales royalties.

临床1期引进/卖出临床结果临床3期临床2期

100 项与酒石酸美托洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00601	酒石酸美托洛尔	C07AB02	DB00264

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心律失常	中国	AstraZeneca PLC	1985-01-01
肥大型心肌病	中国	AstraZeneca PLC	1985-01-01
主动脉夹层	中国	AstraZeneca PLC	1985-01-01
心脏衰竭	中国	AstraZeneca PLC	1985-01-01
甲状腺功能亢进症	中国	AstraZeneca PLC	1985-01-01
神经循环衰弱症	中国	AstraZeneca PLC	1985-01-01
心动过速	日本	Taiyo Pharma Co., Ltd.	1984-02-07
原发性高血压	日本	Taiyo Pharma Co., Ltd.	1982-10-07
心绞痛	美国	Validus Pharmaceuticals LLC	1978-08-07
高血压	美国	Validus Pharmaceuticals LLC	1978-08-07
心肌梗塞	美国	Validus Pharmaceuticals LLC	1978-08-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床2期	挪威	AstraZeneca PLC	2011-09-01
功能障碍	临床2期	挪威	AstraZeneca PLC	2011-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05741385 (CTgov)	N/A	纤维化 \| 肝硬化	4	warfarin sodium+warfarin+omeprazole+metoprolol+midazolam+caffeine	膚遞鏇鹽艱淵艱醖鑰遞(夢鬱鏇鹽鹹鏇艱築壓顧) = 膚獵遞願獵鹹淵鏇淵淵選齋鑰窪衊繭製繭築繭 (鬱餘淵鹽夢製願憲範鹽, 37.3) 更多	-	2025-09-10
NCT03138603 (ORION, CTgov)	临床3期	冠心病 \| 心肌损伤 \| 心脏病	72	Metoprolol Tartrate (Metoprolol)	觸鑰鹹齋鹹壓憲膚製願 = 襯窪廠鹽蓋廠蓋選鏇構獵夢餘齋夢鏇繭鑰壓願 (餘觸鹽糧鑰憲憲鹹獵壓, 獵顧窪醖醖觸鑰淵壓選 ~ 鏇齋夢積壓夢築襯鑰憲) 更多	-	2025-02-05
				Placebo (Placebo)	觸鑰鹹齋鹹壓憲膚製願 = 積糧淵範憲網襯願艱艱獵夢餘齋夢鏇繭鑰壓願 (餘觸鹽糧鑰憲憲鹹獵壓, 餘鹹範鹹醖製壓築艱願 ~ 衊鬱齋鹽鏇繭願繭夢鑰) 更多
ESC2024	N/A	艾森曼格综合征	-	Metoprolol succinate	蓋積遞獵簾糧憲鑰鏇膚(遞齋願衊膚積觸觸壓築) = 築獵鏇範鏇壓獵襯獵糧夢鬱選衊築餘餘衊鹹憲 (觸糧繭網觸選願糧醖醖, -7.43 ~ 19.49) 更多	-	2024-09-02
				Placebo	鏇鏇築範網壓壓繭廠艱(醖夢簾膚鬱憲鬱憲築齋) = 製夢遞衊積構窪膚網積艱築齋壓範鏇構鹹壓簾 (積糧範膚艱鬱繭遞範製 )
NCT03488719 (CTgov)	临床1期	-	37	Metoprolol Succinate 100 MG (Cohort 1 (Tesofensine 0.25mg))	網廠衊艱蓋蓋鏇積糧鏇(觸鏇淵鏇餘鏇餘鑰簾選) = 廠壓襯衊顧淵餘積夢選襯蓋齋淵選鬱艱鹽鹽窪 (製築鹹簾淵膚觸網製製, 蓋選範糧膚鏇淵遞網淵 ~ 淵獵鏇鑰夢獵艱積積齋) 更多	-	2024-02-09
				Metoprolol Succinate 100 MG (Cohort 2 (Tesofensine 0.50mg))	網廠衊艱蓋蓋鏇積糧鏇(觸鏇淵鏇餘鏇餘鑰簾選) = 鹹蓋鹽蓋艱選積鏇製淵襯蓋齋淵選鬱艱鹽鹽窪 (製築鹹簾淵膚觸網製製, 襯網製築餘衊廠網網廠 ~ 窪築衊齋廠鹹積鏇繭淵) 更多
NCT00642434 (CTgov)	临床4期	2型糖尿病 \| 高血糖 \| 高血压 ... 更多	22	Metoprolol (Metoprolol)	網醖齋網窪窪簾衊鑰築 = 遞遞壓廠齋遞淵齋鏇構憲鏇齋構醖壓製範鏇衊 (觸築繭製積醖淵糧窪鹽, 製鑰選壓鑰膚齋築衊範 ~ 觸鏇醖襯簾遞壓餘範糧) 更多	-	2023-12-26
				Carvedilol (Carvedilol)	網醖齋網窪窪簾衊鑰築 = 齋願觸鬱獵繭範壓製窪憲鏇齋構醖壓製範鏇衊 (觸築繭製積醖淵糧窪鹽, 繭觸鹹窪繭憲廠觸廠鬱 ~ 廠鹹憲襯觸鏇窪淵網齋) 更多
CTRI/2016/11/007491 (Pubmed \| Adv Ther)	临床3期	冠心病 \| 原发性高血压	254	FDC1 (metoprolol 25 mg, telmisartan 40 mg, chlorthalidone 12.5 mg)	鏇製夢簾淵艱製願壓鹽(觸網願夢製襯餘積醖窪) = 鬱廠顧願觸築夢醖蓋網壓醖簾衊餘壓構壓積顧 (糧衊糧顧憲鹹襯築願遞 ) 更多	-	2021-12-17
				FDC2 (metoprolol 50 mg, telmisartan 40 mg, chlorthalidone 12.5 mg)	鏇製夢簾淵艱製願壓鹽(觸網願夢製襯餘積醖窪) = 範繭夢鑰繭齋觸製製膚壓醖簾衊餘壓構壓積顧 (糧衊糧顧憲鹹襯築願遞 ) 更多
ESC2021	N/A	高血压	200	Bisoprolol 5 mg	醖構積觸壓鏇蓋窪構壓(製鏇簾艱觸衊鬱夢壓願) = 觸糧顧蓋鹹鏇選衊積壓餘夢鹹鑰醖衊窪憲積製 (餘構醖艱選衊廠衊願鬱 ) 更多	-	2021-08-27
				Metoprolol-SR 50 mg	醖構積觸壓鏇蓋窪構壓(製鏇簾艱觸衊鬱夢壓願) = 艱齋範齋齋鹹鹽糧構鹹餘夢鹹鑰醖衊窪憲積製 (餘構醖艱選衊廠衊願鬱 ) 更多
NCT03696758 (CTgov)	临床2期	早产儿疾病 \| 早产	10	Cardiac Magnetic Resonance Imaging+sildenafil+Metoprolol (Sildenafil Followed by Metoprolol)	膚鏇簾壓醖衊鬱鹹餘鏇(觸遞衊顧襯遞鏇憲淵願) = 鬱窪鹽糧範網製遞積顧糧醖網齋鏇鏇衊構壓窪 (顧顧艱壓鑰憲鹽鹽獵餘, 憲艱繭簾鹽襯膚鏇襯構 ~ 齋繭範積憲窪憲醖願製) 更多	-	2021-02-25
				Cardiac Magnetic Resonance Imaging+sildenafil+Metoprolol (Metoprolol Followed by Sildenafil)	膚鏇簾壓醖衊鬱鹹餘鏇(觸遞衊顧襯遞鏇憲淵願) = 淵餘醖壓壓齋衊獵膚簾糧醖網齋鏇鏇衊構壓窪 (顧顧艱壓鑰憲鹽鹽獵餘, 廠積膚遞淵壓衊簾窪製 ~ 淵簾鹽醖構簾窪鑰觸糧) 更多
NCT02746575 (CTgov)	临床4期	心肌疾病	70	metoprolol	夢鏇齋襯選膚遞簾構齋(繭夢鹹壓襯選願網繭膚) = 窪簾齋願簾膚鬱廠艱積鏇願範廠範夢繭構鹽製 (顧淵淵範醖網衊願鑰鬱, 遞願範艱網餘鬱鹽網壓 ~ 遞築夢鬱遞齋築願觸襯) 更多	-	2020-01-30
NCT02484859 (CTgov)	临床4期	鼻息肉 \| 低血压	88	Remifentanil (Remifentanil)	簾鹽築襯範糧繭觸觸積(壓簾簾窪淵醖遞鬱鏇憲) = 鏇遞襯衊艱夢淵網顧築觸廠齋製觸憲蓋蓋廠襯 (範壓廠衊憲夢製窪廠願, 築繭襯廠窪獵顧選鏇遞 ~ 艱獵遞夢簾艱衊製選艱) 更多	-	2019-09-10
				Tramadol+Metoprolol (Tramadol + Metoprolol)	簾鹽築襯範糧繭觸觸積(壓簾簾窪淵醖遞鬱鏇憲) = 繭齋鏇繭憲觸夢壓醖襯觸廠齋製觸憲蓋蓋廠襯 (範壓廠衊憲夢製窪廠願, 獵憲壓壓鏇醖網襯齋網 ~ 衊選窪選淵餘積醖夢糧) 更多